{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:23:02Z","timestamp":1790392982797,"version":"4.1.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,4,23]],"date-time":"2013-04-23T00:00:00Z","timestamp":1366675200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s40258-013-0014-4","type":"journal-article","created":{"date-parts":[[2013,4,22]],"date-time":"2013-04-22T16:02:10Z","timestamp":1366646530000},"page":"205-218","source":"Crossref","is-referenced-by-count":12,"title":["Multilevel Analysis of the Influence of Patients\u2019 and General Practitioners\u2019 Characteristics on Patented Versus Multiple-Sourced Statin Prescribing in France"],"prefix":"10.1007","volume":"11","author":[{"given":"Sylvain","family":"Pichetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Sermet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Godman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars L.","family":"Gustafsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,4,23]]},"reference":[{"issue":"1","key":"14_CR1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/BF03256162","volume":"8","author":"C Sermet","year":"2010","unstructured":"Sermet C, Andrieu V, Godman B, et al. Ongoing pharmaceutical reforms in France: implications for key stakeholder groups. Appl Health Econ Health Policy. 2010;8(1):7\u201324.","journal-title":"Appl Health Econ Health Policy"},{"issue":"4","key":"14_CR2","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1586\/14737167.8.4.357","volume":"8","author":"B Godman","year":"2008","unstructured":"Godman B, Bucsics A, Burkhardt T, et al. Insight into recent reforms and initiatives in Austria: implications for key stakeholders. Expert Rev Pharmacoecon Outcomes Res. 2008;8(4):357\u201371.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"7","key":"14_CR3","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2165\/00019053-200826070-00001","volume":"26","author":"B Wettermark","year":"2008","unstructured":"Wettermark B, Godman B, Andersson K, et al. Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe. Pharmacoeconomics. 2008;26(7):537\u201350.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"14_CR4","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1586\/erp.10.72","volume":"10","author":"B Godman","year":"2010","unstructured":"Godman B, Shrank W, Andersen M, et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Rev Pharmacoecon Outcomes Res. 2010;10(6):707\u201322.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"14_CR5","first-page":"141","volume":"1","author":"B Godman","year":"2010","unstructured":"Godman B, Shrank W, Andersen M, et al. Policies to enhance prescribing efficiency in europe: findings and future implications. Front Pharmacol. 2010;1:141.","journal-title":"Front Pharmacol"},{"key":"14_CR6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.7175\/rhc.v3i1.55","volume":"3","author":"B Godman","year":"2012","unstructured":"Godman B, Malmstrom RE, Bennie M, et al. Prescribing restrictions\u2014a necessary strategy among some European countries to enhance future prescribing efficiency? Rev Health Care. 2012;3:5\u201316.","journal-title":"Rev Health Care"},{"issue":"12","key":"14_CR7","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s00228-008-0537-z","volume":"64","author":"S Garattini","year":"2008","unstructured":"Garattini S, Bertele\u2019 V, Godman B, et al. Enhancing the rational use of new medicines across European health care systems. Eur J Clin Pharmacol. 2008;64(12):1137\u20138.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"14_CR8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1586\/14737167.9.1.65","volume":"9","author":"B Godman","year":"2009","unstructured":"Godman B, Wettermark B, Hoffmann M, et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev Pharmacoecon Outcomes Res. 2009;9(1):65\u201383.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"14_CR9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1586\/erp.09.73","volume":"10","author":"D McGinn","year":"2010","unstructured":"McGinn D, Godman B, Lonsdale J, et al. Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications. Expert Rev Pharmacoecon Outcomes Res. 2010;10(1):73\u201385.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"14_CR10","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.3390\/ph3082470","volume":"3","author":"B Godman","year":"2010","unstructured":"Godman B, Shrank W, Wettermark B, et al. Use of generics\u2014a critical cost containment measure for all healthcare professionals in Europe? Pharmaceuticals. 2010;3:2470\u201394.","journal-title":"Pharmaceuticals"},{"issue":"3","key":"14_CR11","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1586\/erp.11.24","volume":"11","author":"K Garuoliene","year":"2011","unstructured":"Garuoliene K, Godman B, Gulbinovic J, et al. European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Expert Rev Pharmacoecon Outcomes Res. 2011;11(3):343\u20139.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"6","key":"14_CR12","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1586\/erp.09.58","volume":"9","author":"A Coma","year":"2009","unstructured":"Coma A, Zara C, Godman B, et al. Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction. Expert Rev Pharmacoecon Outcomes Res. 2009;9(6):569\u201381.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"14_CR13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.5639\/gabij.2012.0101.007","volume":"1","author":"B Godman","year":"2012","unstructured":"Godman B, Wettermark B, Bishop I, et al. European payer initiatives to reduce prescribing costs through use of generics. GABI. 2012;1:22\u20137.","journal-title":"GABI"},{"issue":"1","key":"14_CR14","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.healthpol.2011.10.010","volume":"104","author":"B Pettersson","year":"2012","unstructured":"Pettersson B, Hoffmann M, Wandell P, et al. Utilization and costs of lipid modifying therapies following health technology assessment for the new reimbursement scheme in Sweden. Health Policy. 2012;104(1):84\u201391.","journal-title":"Health Policy"},{"key":"14_CR15","doi-asserted-by":"crossref","unstructured":"Vrijens F, Van de Voorde C, Farfan-Portet MI et al. Patient socioeconomic determinants for the choice of the cheapest molecule within a cluster: evidence from Belgian prescription data. Eur J Health Econ. 2012; 13(3):315\u2013325.","DOI":"10.1007\/s10198-011-0367-2"},{"issue":"3","key":"14_CR16","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.healthpol.2009.09.014","volume":"94","author":"B Wettermark","year":"2010","unstructured":"Wettermark B, Godman B, Neovius M, et al. Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment. Health Policy. 2010;94(3):221\u20139.","journal-title":"Health Policy"},{"issue":"3","key":"14_CR17","first-page":"179","volume":"17","author":"B Wettermark","year":"2009","unstructured":"Wettermark B, Pehrsson A, Juhasz-Haverinen M, et al. Financial incentives linked to self-assessment of prescribing patterns: a new approach for quality improvement of drug prescribing in primary care. Qual Prim Care. 2009;17(3):179\u201389.","journal-title":"Qual Prim Care"},{"issue":"4","key":"14_CR18","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1742-7843.2011.00682.x","volume":"108","author":"LL Gustafsson","year":"2011","unstructured":"Gustafsson LL, Wettermark B, Godman B, et al. The \u2018wise list\u2019\u2014a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin Pharmacol Toxicol. 2011;108(4):224\u201333.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"9","key":"14_CR19","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/MLR.0b013e3181e41bcb","volume":"48","author":"JE Martikainen","year":"2010","unstructured":"Martikainen JE, Saastamoinen LK, Korhonen MJ, et al. Impact of restricted reimbursement on the use of statins in Finland: a register-based study. Med Care. 2010;48(9):761\u20136.","journal-title":"Med Care"},{"issue":"4","key":"14_CR20","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1586\/erp.11.42","volume":"11","author":"L Voncina","year":"2011","unstructured":"Voncina L, Strizrep T, Godman B, et al. Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future. Expert Rev Pharmacoecon Outcomes Res. 2011;11(4):469\u201379.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"14_CR21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1586\/erp.10.87","volume":"11","author":"B Godman","year":"2011","unstructured":"Godman B, Sakshaug S, Berg C, et al. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. Expert Rev Pharmacoecon Outcomes Res. 2011;11(1):121\u20139.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"7","key":"14_CR22","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ijmedinf.2006.02.010","volume":"76","author":"B Sjoborg","year":"2007","unstructured":"Sjoborg B, Backstrom T, Arvidsson LB, et al. Design and implementation of a point-of-care computerized system for drug therapy in Stockholm metropolitan health region\u2013Bridging the gap between knowledge and practice. Int J Med Inform. 2007;76(7):497\u2013506.","journal-title":"Int J Med Inform"},{"issue":"3","key":"14_CR23","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1345\/aph.1L488","volume":"43","author":"R Ostini","year":"2009","unstructured":"Ostini R, Hegney D, Jackson C, et al. Systematic review of interventions to improve prescribing. Ann Pharmacother. 2009;43(3):502\u201313.","journal-title":"Ann Pharmacother"},{"issue":"Suppl 1","key":"14_CR24","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1093\/fampra\/17.suppl_1.S7","volume":"17","author":"N Freemantle","year":"2000","unstructured":"Freemantle N. Implementation strategies. Fam Pract. 2000;17(Suppl 1):S7\u201310.","journal-title":"Fam Pract"},{"key":"14_CR25","doi-asserted-by":"crossref","unstructured":"O\u2019Brien MA, Rogers S, Jamtvedt G et al. Educational outreach visits: effects on professional practice and health care outcomes. Cochrane Database Syst Rev. 2007;(4):CD000409.","DOI":"10.1002\/14651858.CD000409.pub2"},{"issue":"3","key":"14_CR26","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/BF03256147","volume":"7","author":"B Wettermark","year":"2009","unstructured":"Wettermark B, Godman B, Jacobsson B, et al. Soft regulations in pharmaceutical policy making: an overview of current approaches and their consequences. Appl Health Econ Health Policy. 2009;7(3):137\u201347.","journal-title":"Appl Health Econ Health Policy"},{"issue":"2","key":"14_CR27","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5639\/gabij.2012.0102.017","volume":"1","author":"B Godman","year":"2012","unstructured":"Godman B, Abuelkhair M, Vitry A, et al. Payers endorse generics to enhance prescribing efficiency; impact and future implications, a case history approach. GABI. 2012;1(2):69\u201383.","journal-title":"GABI"},{"key":"14_CR28","unstructured":"Cour des Comptes. Rapport annuel sur la s\u00e9curit\u00e9 sociale. La ma\u00eetrise des d\u00e9penses de m\u00e9dicaments 2010. 2011. Available at http:\/\/www.ccomptes.fr\/Publications\/Publications\/Securite-sociale-2011 . Accessed 18 Mar 2013."},{"issue":"4","key":"14_CR29","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1586\/erp.12.44","volume":"12","author":"B Godman","year":"2012","unstructured":"Godman B, Paterson K, Malmstrom RE, et al. Improving the managed entry of new medicines: sharing experiences across Europe. Expert Rev Pharmacoecon Outcomes Res. 2012;12(4):439\u201341.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"14_CR30","unstructured":"Convention nationale organisant les rapports entre les m\u00e9decins lib\u00e9raux et l\u2019Assurance maladie JORF n\u00b00223 du 25 septembre 2011, page 16080 texte n\u00b016."},{"issue":"2","key":"14_CR31","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2710.2009.01085.x","volume":"35","author":"TC Weng","year":"2010","unstructured":"Weng TC, Yang YH, Lin SJ, et al. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther. 2010;35(2):139\u201351.","journal-title":"J Clin Pharm Ther"},{"issue":"9","key":"14_CR32","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/j.1742-1241.2009.02129.x","volume":"63","author":"C Norman","year":"2009","unstructured":"Norman C, Zarrinkoub R, Hasselstrom J, et al. Potential savings without compromising the quality of care. Int J Clin Pract. 2009;63(9):1320\u20136.","journal-title":"Int J Clin Pract"},{"issue":"3","key":"14_CR33","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1742-1241.2007.01690.x","volume":"62","author":"J Usher-Smith","year":"2008","unstructured":"Usher-Smith J, Ramsbottom T, Pearmain H, et al. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2\u00a0years on. Int J Clin Pract. 2008;62(3):480\u20134.","journal-title":"Int J Clin Pract"},{"issue":"4","key":"14_CR34","first-page":"366","volume":"30","author":"M Boh","year":"2011","unstructured":"Boh M, Opolski G, Poredos P, et al. Therapeutic equivalence of the generic and the reference atorvastatin in patients with increased coronary risk. Int Angiol. 2011;30(4):366\u201374.","journal-title":"Int Angiol"},{"key":"14_CR35","unstructured":"French National Authority for Health. Efficacit\u00e9 et efficience des hypolip\u00e9miants: une analyse centr\u00e9e sur les statines. 2012. Available at http:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/2010-09\/5_statines-argumentaire_complet_maj_sept_2010.pdf . Accessed 18 Mar 2013."},{"issue":"1","key":"14_CR36","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1586\/erp.11.98","volume":"12","author":"M Bennie","year":"2012","unstructured":"Bennie M, Godman B, Bishop I, et al. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. Expert Rev Pharmacoecon Outcomes Res. 2012;12(1):125\u201330.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"3","key":"14_CR37","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10198-006-0023-4","volume":"8","author":"S Bejean","year":"2007","unstructured":"Bejean S, Peyron C, Urbinelli R. Variations in activity and practice patterns: a French study for GPs. Eur J Health Econ. 2007;8(3):225\u201336.","journal-title":"Eur J Health Econ"},{"issue":"4","key":"14_CR38","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1258\/135581902320432723","volume":"7","author":"P Davis","year":"2002","unstructured":"Davis P, Gribben B, Lay-Yee R, et al. How much variation in clinical activity is there between general practitioners? A multi-level analysis of decision-making in primary care. J Health Serv Res Policy. 2002;7(4):202\u20138.","journal-title":"J Health Serv Res Policy"},{"issue":"4","key":"14_CR39","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/fampra\/16.4.407","volume":"16","author":"FH Steffensen","year":"1999","unstructured":"Steffensen FH, Sorensen HT, Olesen F. Diffusion of new drugs in Danish general practice. Fam Pract. 1999;16(4):407\u201313.","journal-title":"Fam Pract"},{"issue":"8","key":"14_CR40","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1097\/00005650-200308000-00004","volume":"41","author":"R Tamblyn","year":"2003","unstructured":"Tamblyn R, McLeod P, Hanley JA, et al. Physician and practice characteristics associated with the early utilization of new prescription drugs. Med Care. 2003;41(8):895\u2013908.","journal-title":"Med Care"},{"key":"14_CR41","unstructured":"Tollen L. Physician organization in relation to quality and efficiency of care. A synthesis of recent literature. 2008. Kaiser Permanente Institute for Health Policy, the Commonwealth Fund."},{"issue":"11","key":"14_CR42","doi-asserted-by":"crossref","first-page":"826","DOI":"10.7326\/0003-4819-145-11-200612050-00007","volume":"145","author":"A Mehrotra","year":"2006","unstructured":"Mehrotra A, Epstein AM, Rosenthal MB. Do integrated medical groups provide higher-quality medical care than individual practice associations? Ann Intern Med. 2006;145(11):826\u201333.","journal-title":"Ann Intern Med"},{"issue":"12","key":"14_CR43","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1136\/adc.2004.050468","volume":"89","author":"IC Wong","year":"2004","unstructured":"Wong IC, Murray ML, Camilleri-Novak D, et al. Increased prescribing trends of paediatric psychotropic medications. Arch Dis Child. 2004;89(12):1131\u20132.","journal-title":"Arch Dis Child"},{"issue":"2\u20133","key":"14_CR44","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.healthpol.2011.07.001","volume":"102","author":"S Pichetti","year":"2011","unstructured":"Pichetti S, Sorasith C, Sermet C. Analysis of the impact of removing mucolytics and expectorants from the list of reimbursable drugs on prescription rates: a time-series analysis for France 1998\u20132010. Health Policy. 2011;102(2\u20133):159\u201369.","journal-title":"Health Policy"},{"key":"14_CR45","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/0141192910170408","volume":"17","author":"L Paterson","year":"1991","unstructured":"Paterson L, Goldstein H. New statistical methods for analysing social structures : an introduction to multilevel models. British Educational Res J. 1991;17:387\u201393.","journal-title":"British Educational Res J"},{"key":"14_CR46","doi-asserted-by":"crossref","unstructured":"Geleedst-De VM, Maitland-van der Zee AH, Schalekamp T et al. Statin prescribing in the elderly in the Netherlands: a pharmacy database time trend study. Drugs Aging. 2010; 27(7):589\u2013596.","DOI":"10.2165\/11537330-000000000-00000"},{"key":"14_CR47","doi-asserted-by":"crossref","unstructured":"Heck R, Thomas S. An introduction of multilevel modelling technics. New York: Routledge; 1999.","DOI":"10.4324\/9781410604767"},{"key":"14_CR48","unstructured":"Raudenbush S, Bryk A. Hierarchical linear models. Applications and data analysis methods. SAGE Publications Inc.: Osborne; 2002."},{"issue":"1","key":"14_CR49","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/1467-9868.00106","volume":"60","author":"D Pfeffermann","year":"1998","unstructured":"Pfeffermann D, Skinner CJ, Holmes DJ, et al. Weighting for unequal selection probabilities in multilevel models. J R Stat Soc Ser B (statistical methodology). 1998;60(1):23\u201340.","journal-title":"J R Stat Soc Ser B (statistical methodology)"},{"issue":"415","key":"14_CR50","first-page":"91","volume":"47","author":"L Templeton","year":"1997","unstructured":"Templeton L, Deehan A, Taylor C, et al. Surveying general practitioners: does a low response rate matter? Br J Gen Pract. 1997;47(415):91\u20134.","journal-title":"Br J Gen Pract"},{"issue":"2","key":"14_CR51","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/fampra\/cmn015","volume":"25","author":"E Hummers-Pradier","year":"2008","unstructured":"Hummers-Pradier E, Scheidt-Nave C, Martin H, et al. Simply no time? Barriers to GPs\u2019 participation in primary health care research. Fam Pract. 2008;25(2):105\u201312.","journal-title":"Fam Pract"},{"issue":"9","key":"14_CR52","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/archinternmed.2009.64","volume":"169","author":"D Grande","year":"2009","unstructured":"Grande D, Frosch DL, Perkins AW, et al. Effect of exposure to small pharmaceutical promotional items on treatment preferences. Arch Intern Med. 2009;169(9):887\u201393.","journal-title":"Arch Intern Med"},{"issue":"5","key":"14_CR53","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1365-2710.2008.00948.x","volume":"33","author":"GJ Kyle","year":"2008","unstructured":"Kyle GJ, Nissen LM, Tett SE. Pharmaceutical company influences on medication prescribing and their potential impact on quality use of medicines. J Clin Pharm Ther. 2008;33(5):553\u20139.","journal-title":"J Clin Pharm Ther"},{"issue":"7","key":"14_CR54","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s11606-009-0989-6","volume":"24","author":"MA Fischer","year":"2009","unstructured":"Fischer MA, Keough ME, Baril JL, et al. Prescribers and pharmaceutical representatives: why are we still meeting? J Gen Intern Med. 2009;24(7):795\u2013801.","journal-title":"J Gen Intern Med"},{"issue":"11","key":"14_CR55","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1016\/j.socscimed.2006.07.019","volume":"63","author":"JP Greving","year":"2006","unstructured":"Greving JP, Denig P, van der Veen WJ, et al. Determinants for the adoption of angiotensin II receptor blockers by general practitioners. Soc Sci Med. 2006;63(11):2890\u20138.","journal-title":"Soc Sci Med"},{"issue":"1","key":"14_CR56","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/fampra\/20.1.61","volume":"20","author":"H Prosser","year":"2003","unstructured":"Prosser H, Almond S, Walley T. Influences on GPs\u2019 decision to prescribe new drugs-the importance of who says what. Fam Pract. 2003;20(1):61\u20138.","journal-title":"Fam Pract"},{"issue":"7309","key":"14_CR57","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1136\/bmj.323.7309.378","volume":"323","author":"MI Jones","year":"2001","unstructured":"Jones MI, Greenfield SM, Bradley CP. Prescribing new drugs: qualitative study of influences on consultants and general practitioners. BMJ. 2001;323(7309):378\u201381.","journal-title":"BMJ"},{"key":"14_CR58","unstructured":"Tobin L, de Almedia Neto AC, Wutzke S et al. Influences on the prescribing of new drugs. Aust Fam Physician. 2008; 37(1\u20132): 78\u201380, 83."},{"issue":"7400","key":"14_CR59","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1136\/bmj.326.7400.1178","volume":"326","author":"C Watkins","year":"2003","unstructured":"Watkins C, Moore L, Harvey I, et al. Characteristics of general practitioners who frequently see drug industry representatives: national cross sectional study. BMJ. 2003;326(7400):1178\u20139.","journal-title":"BMJ"},{"issue":"5","key":"14_CR60","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/fampra\/cmg516","volume":"20","author":"H Prosser","year":"2003","unstructured":"Prosser H, Walley T. New drug uptake: qualitative comparison of high and low prescribing GPs\u2019 attitudes and approach. Fam Pract. 2003;20(5):583\u201391.","journal-title":"Fam Pract"},{"issue":"6","key":"14_CR61","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2165\/11539150-000000000-00000","volume":"10","author":"P Plans-Rubio","year":"2010","unstructured":"Plans-Rubio P. The cost effectiveness of statin therapies in Spain in 2010, after the introduction of generics and reference prices. Am J Cardiovasc Drugs. 2010;10(6):369\u201382.","journal-title":"Am J Cardiovasc Drugs"},{"key":"14_CR62","first-page":"20","volume":"16","author":"L Voncina","year":"2011","unstructured":"Voncina L, Strizrep T. Croatia 2009\/2010. Pharmaceutical pricing and reimbursement reform. Eurohealth. 2011;16:20\u20132.","journal-title":"Eurohealth"},{"issue":"8","key":"14_CR63","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.socscimed.2009.12.016","volume":"70","author":"J Mousques","year":"2010","unstructured":"Mousques J, Renaud T, Scemama O. Is the \u201cpractice style\u201d hypothesis relevant for general practitioners? An analysis of antibiotics prescription for acute rhinopharyngitis. Soc Sci Med. 2010;70(8):1176\u201384.","journal-title":"Soc Sci Med"},{"key":"14_CR64","unstructured":"Bras PL, Ricordeau P, Roussille B et al. GP\u2019s information on medicines. L\u2019information des m\u00e9decins g\u00e9n\u00e9ralistes sur le m\u00e9dicament. Rapport de l\u2019IGAS, September 2007."},{"issue":"11","key":"14_CR65","first-page":"730","volume":"11","author":"TB Gibson","year":"2005","unstructured":"Gibson TB, Ozminkowski RJ, Goetzel RZ. The effects of prescription drug cost sharing: a review of the evidence. Am J Manag Care. 2005;11(11):730\u201340.","journal-title":"Am J Manag Care"},{"key":"14_CR66","doi-asserted-by":"crossref","unstructured":"Green CJ, Maclure M, Fortin PM et al. Pharmaceutical policies: effects of restrictions on reimbursement. Cochrane Database Syst Rev 2010; (8):CD008654.","DOI":"10.1002\/14651858.CD008654"},{"issue":"7156","key":"14_CR67","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/bmj.317.7156.465","volume":"317","author":"LA Bero","year":"1998","unstructured":"Bero LA, Grilli R, Grimshaw JM, et al. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group. BMJ. 1998;317(7156):465\u20138.","journal-title":"BMJ"},{"issue":"7285","key":"14_CR68","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1136\/bmj.322.7285.503","volume":"322","author":"S Barton","year":"2001","unstructured":"Barton S. Using clinical evidence. BMJ. 2001;322(7285):503\u20134.","journal-title":"BMJ"},{"key":"14_CR69","unstructured":"Abernethy D, Birkett D, Brosen K, Cascorbi I, Gustafsson LL, Hoppu K, Maxwll S, Orme M, Rago L, Rawlin M Sir, Reidenberg M, Sj\u00f6qvist F, Smith T, Thuerman P, Walubo A. Clinical pharmacology in health care, teaching and research. Joint publication by WHO, CIOMS and IUPHAR (International Union of Pharmacology and Clinical Pharmacology) edited by Orme M, Sj\u00f6qvist F and Birkett D, Geneva 2012, Oct 8. Available at www.cioms.ch\/index.php\/component\/booklibrary\/?task=view&Itemid=&id=46&catid=58 . Accessed 18 Jan 2013."}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-013-0014-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40258-013-0014-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-013-0014-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T16:06:56Z","timestamp":1644854816000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40258-013-0014-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,23]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["14"],"URL":"https:\/\/doi.org\/10.1007\/s40258-013-0014-4","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,23]]}}}